News
Today bioMérieux released its 2023 financial results. Consolidated sales amounted to €3,675 million in 2023, up 6.6% like-for-like from €3,589 million in the prior year period.
Swipe to discover more
-
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of two new Executive Committee members: Dr. Charles K. Cooper as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024; Céline Roger-Dalbert as Executive Vice President Research and Development, effective March 1st, 2024. -
Antimicrobial Resistance Makes It Harder to Treat Urinary Tract Infections and Increases Risk of Sepsis and AKI
Antimicrobial resistant bacteria pose a major public health threat because they limit treatment options for infectious diseases. Common ailments like urinary tract infections (UTIs), which have often been easily and quickly cured by antibiotics historically, are becoming harder to treat due to resistant bacteria. Not only does this prolong discomfort for those suffering from UTIs, it also presents the danger that the infection may lead to a more serious condition. -
bioMérieux and the University of Pittsburgh Form Research Partnership
A strategic R&D partnership between bioMérieux and the University of Pittsburgh (Pitt) has been launched, paving the way for many innovative and collaborative research projects.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19